ECOG 2205: Title: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-operative Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of the Esophagus.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Docetaxel; Fluorouracil; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms E2205

Most Recent Events

21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect)
30 Jun 2009 Additional lead trial investigator identified as reported by New Jersey Cancer Trial Connect

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight